How Radiation Therapy Works, From DNA Damage to Modern Precision Treatment

Radiation therapy sounds simple: aim high-energy beams at a tumor and destroy it. The biology underneath that idea is more interesting, and understanding it explains why treatment is scheduled the way it is, why some tumors respond poorly, and why doctors increasingly pair radiation with other treatments.

How Radiation Breaks Cancer Cells Apart

Ionizing radiation, the kind used in cancer treatment, carries enough energy to knock electrons loose from atoms. Inside a cell, that energy does its real damage to DNA, the molecule that stores a cell's instructions. The most dangerous injury is a double-strand break, where both strands of the DNA helix snap at the same spot. A cell can often patch a break in just one strand using the other as a template, the way you might fix a torn page by copying from a duplicate. A break in both strands at once removes that backup copy, which makes it far harder to repair correctly.

Radiation causes these breaks two ways. Sometimes it strikes the DNA directly. More often, especially with the X-rays and gamma rays used in clinics, it hits water molecules inside the cell instead, since cells are mostly water. That collision creates short-lived, highly reactive fragments called free radicals, which then go on to damage nearby DNA. Either route can leave a double-strand break that the cell struggles to repair cleanly, and enough unrepaired or badly repaired breaks eventually cause the cell to die or stop dividing.

Why Treatment Comes in Many Small Doses, Not One Big One

Most radiation schedules spread the total dose across many smaller daily sessions instead of delivering it all at once. This idea, formalized decades ago by radiobiologist H. Rodney Withers as the "four Rs of radiotherapy," rests on real differences between how normal tissue and tumor tissue respond to repeated injury.

Healthy cells tend to repair sub-lethal DNA damage more efficiently than cancer cells, so spacing out treatment gives normal tissue recovery time between hits while tumor cells accumulate damage they cannot keep up with. Fractionation also helps because tumor cells move through different phases of their division cycle, and radiation is more lethal at some phases than others, so repeated dosing over days catches cells at their most vulnerable moments. A third factor is reoxygenation, which matters enough that it deserves its own explanation.

The Oxygen Problem: Why Some Tumors Resist Radiation

Oxygen turns out to be a quiet but critical ingredient in how well radiation works. When free radicals damage DNA, oxygen helps "fix" that damage into a stable, lasting break. Without enough oxygen present, some of the damage can actually be chemically reversed before it does lasting harm, an effect first demonstrated experimentally in the 1950s and now known simply as the oxygen effect.

This matters because tumors often contain regions of hypoxia, where oxygen levels are lower than in normal tissue, usually because a tumor's blood supply is disorganized and cannot keep up with its growth. Cells in those low-oxygen pockets can be markedly more resistant to a given dose of radiation than well-oxygenated cells nearby. Fractionation helps here too: as treatment kills off the better-oxygenated cells at the tumor's edge, blood flow can improve to previously starved regions between sessions, allowing some previously resistant cells to become more vulnerable over the course of treatment.

Aiming More Precisely

Older radiotherapy delivered a roughly uniform beam that inevitably passed through healthy tissue on its way to the tumor. Intensity-modulated radiation therapy, or IMRT, instead shapes and varies the beam's intensity across many small segments so the dose matches the tumor's actual contours. In head and neck cancer, a large randomized trial found that this approach meaningfully reduced long-term dry mouth caused by damage to the salivary glands, compared with conventional radiotherapy, without giving up tumor coverage.

For small, well-defined tumors, an even more focused approach called stereotactic radiosurgery delivers a high dose in very few sessions, sometimes just one. It is used for certain brain tumors and other small targets where extreme precision allows a higher dose with less spillover into surrounding tissue. These techniques are powerful tools, but which one suits a particular cancer depends on its size, location, and how it behaves, not on the newest technology being automatically the best fit.

Pairing Radiation With Chemotherapy and Immunotherapy

Radiation is frequently combined with chemotherapy, an approach called chemoradiation, because the two treatments can reinforce each other, with chemotherapy drugs often making cells more susceptible to radiation damage. In locally advanced cervical cancer, adding cisplatin-based chemotherapy to radiation improved survival compared with radiation given alone. In head and neck cancer, a large analysis pooling dozens of trials found that adding chemotherapy to radiotherapy improved survival, with the benefit clearest when the two were given at the same time rather than one after the other. A similar pattern held in locally advanced non-small cell lung cancer, where giving chemotherapy and radiation concurrently outperformed giving them in sequence.

More recently, researchers have explored combining radiation with immune checkpoint inhibitors, drugs that release natural brakes on the immune system's ability to attack cancer. In animal studies, radiation paired with two checkpoint-blocking drugs together produced stronger anti-tumor immune activity than either treatment alone, suggesting the combination engages immune mechanisms that neither one triggers by itself. This remains an active area of research rather than a settled treatment approach for most cancers.

Can Radiation Affect Tumors It Never Touches?

Occasionally, treating one tumor appears to coincide with shrinkage of a separate, untreated tumor elsewhere in the body. This is known as the abscopal effect, and early laboratory work by Sandra Demaria's group showed it depends on a functioning immune system: radiation seems to expose tumor material in a way that primes immune cells to then recognize and attack cancer at distant sites. The effect remains rare and unpredictable in practice, which is part of why it has become a major motivation for the checkpoint-inhibitor combination research described above, rather than something patients can expect or plan around.

Weighing the Long-Term Risks

Radiation's effects on DNA are not selective enough to spare every healthy cell nearby, and that carries a long-term consequence. Large population studies tracking cancer patients for years after treatment have found a measurable, but relatively small, increase in the risk of developing a new, separate cancer in tissue that was previously irradiated. This risk needs context: it typically emerges many years after treatment, affects a minority of patients, and has to be weighed against the direct benefit radiation provides against the original cancer. For this reason, radiation therapy remains a standard part of cancer care, with the decision to use it made individually by an oncology team weighing these trade-offs.

Matching the Technique to the Cancer

Not every situation calls for the same radiation strategy, and more treatment is not always better. For early-stage breast cancer, trials comparing a shorter schedule of fewer, larger daily doses against the traditional longer schedule found the shorter approach to be just as effective and just as safe, a finding that has reshaped how many patients are treated. For patients with a limited number of brain metastases, adding focused radiosurgery to whole-brain radiotherapy improved control of the treated tumors but did not extend overall survival compared with radiosurgery combined with whole-brain treatment alone, illustrating that local tumor control and survival benefit do not always move together. These findings underscore a broader point: the right radiation approach depends on the cancer type, its location, how advanced it is, and the individual patient, decisions made by radiation oncologists rather than dictated by a single universal rule.